Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI‐1 study
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI‐1 study
Authors
Keywords
-
Journal
CANCER SCIENCE
Volume 111, Issue 2, Pages 513-527
Publisher
Wiley
Online
2019-12-03
DOI
10.1111/cas.14264
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics
- (2018) Femke M. de Man et al. CLINICAL PHARMACOKINETICS
- Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline Update
- (2018) Davendra P.S. Sohal et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018
- (2018) J. Ferlay et al. EUROPEAN JOURNAL OF CANCER
- TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial)
- (2018) Tatsuya Ioka et al. EUROPEAN JOURNAL OF CANCER
- Regional differences in advanced gastric cancer: exploratory analyses of the AVAGAST placebo arm
- (2017) Akira Sawaki et al. Gastric Cancer
- nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: a subgroup analysis of the Western European cohort of the MPACT trial
- (2017) Josep Tabernero et al. OncoTargets and Therapy
- A phase I dose-escalation study of PEP02 (irinotecan liposome injection) in combination with 5-fluorouracil and leucovorin in advanced solid tumors
- (2016) Nai-Jung Chiang et al. BMC CANCER
- Development of nanoliposomal irinotecan (nal-IRI, MM-398, PEP02) in the management of metastatic pancreatic cancer
- (2016) Nai-Jung Chiang et al. EXPERT OPINION ON PHARMACOTHERAPY
- Pancreatic cancer
- (2016) Terumi Kamisawa et al. LANCET
- Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial
- (2016) Andrea Wang-Gillam et al. LANCET
- PEPCOL: a GERCOR randomized phase II study of nanoliposomal irinotecan PEP02 (MM-398) or irinotecan with leucovorin/5-fluorouracil as second-line therapy in metastatic colorectal cancer
- (2016) Benoist Chibaudel et al. Cancer Medicine
- A randomized phase II study of S-1 plus oral leucovorin versus S-1 monotherapy in patients with gemcitabine-refractory advanced pancreatic cancer
- (2015) M. Ueno et al. ANNALS OF ONCOLOGY
- Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer
- (2015) S Ohkawa et al. BRITISH JOURNAL OF CANCER
- Preclinical Activity of Nanoliposomal Irinotecan Is Governed by Tumor Deposition and Intratumor Prodrug Conversion
- (2014) A. V. Kalra et al. CANCER RESEARCH
- Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States
- (2014) L. Rahib et al. CANCER RESEARCH
- A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma†
- (2013) A. C. Roy et al. ANNALS OF ONCOLOGY
- Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study
- (2013) Hideki Ueno et al. JOURNAL OF CLINICAL ONCOLOGY
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study
- (2011) Atsushi Ohtsu et al. JOURNAL OF CLINICAL ONCOLOGY
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer
- (2009) C Yoo et al. BRITISH JOURNAL OF CANCER
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now